Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.63 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.63 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-0299685 SCHEMBL4382735 | 1.00 | CACNA2D1 (0.63) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL119378 | 1.00 | CACNA2D1 (0.63) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL3124421 | 1.00 | CACNA2D1 (0.63) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL1923707 | 1.00 | CACNA2D1 (0.63) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL1923704 | 1.00 | CACNA2D1 (0.63) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL25912 | 1.00 | CACNA2D1 (0.63) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL3123592 | 0.98 | CACNA2D1 (0.61) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL3828529 | 0.98 | CACNA2D1 (0.61) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL4378882 | 0.98 | CACNA2D1 (0.61) | CACNA2D1ADRA1ACACNB3CACNA1CPGR | |
| Pd-0299685 SCHEMBL3828531 | 0.98 | CACNA2D1 (0.61) | CACNA2D1ADRA1ACACNB3CACNA1CPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125021-B8 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH ALPHA 2DELTA LIGANDS AND NSAIDS | RECORDATI IRELAND LTD (IE) | 2012-02-15 | — | — | EP | claimed |
| EP-2125021-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH 2 LIGANDS AND NSAIDS | Recordati Ireland Limited (IE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077599-A1 | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS | RECORDATI IRELAND LIMITED (IE) | 2008-07-03 | — | — | WO | claimed |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| EP-2017259-A2 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | Pfizer Products Inc. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-7432299-B2 | Method of treatment for sexual dysfunction | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432299-B2 | Method of treatment for sexual dysfunction | PFIZER INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1973867-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | Pfizer Products Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007072159-A1 | PREPARATION OF GAMMA-AMINO ACIDS HAVING AFFINITY FOR THE ALPHA-2-DELTA PROTEIN | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | PFIZER INC | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070141684-A1 | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | SCN2A, CACNG2, SCN1A | CACNA2D1 26/4885ADRA1A 118/4885CACNB3 56/4885 |
| US-20090299093-A1 | Preparation of Gamma-Amino Acids Having Affinity for The Alpha-2-Delta Protein | SCN2A, CACNG2, SCN1A | CACNA2D1 26/4885ADRA1A 118/4885CACNB3 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.